Literature DB >> 559662

Evaluation of induced infections as a research method.

F H Newbould.   

Abstract

Induced intramammary infections have been used to elucidate the route of invasion and the response of the gland once invading microorganisms have entered the teat cistern. Currently, such infections have been employed to study factors affecting the efficacy and excretion of antibiotic and chemotherapeutic products infused into the mammary gland for treatment and control of mastitis. They provide a means for controlled standardized conditions which cannot be obtained in commercial herds often employed in field studies.

Entities:  

Mesh:

Year:  1977        PMID: 559662

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  5 in total

1.  The use of induced mammary infections for evaluating dry cow treatment products. I. Development of a method.

Authors:  F H Newbould
Journal:  Can J Comp Med       Date:  1979-10

2.  Posology and field efficacy study with novobiocin for intramammary infusion in nonlactating dairy cows.

Authors:  G H Swenson
Journal:  Can J Comp Med       Date:  1979-10

3.  Escherichia coli and Staphylococcus aureus elicit differential innate immune responses following intramammary infection.

Authors:  Douglas D Bannerman; Max J Paape; Jai-Wei Lee; Xin Zhao; Jayne C Hope; Pascal Rainard
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

4.  Experimental Staphylococcus aureus Mastitis Infection Model by Teat Dipping in Bacterial Culture Suspension in Dairy Cows.

Authors:  Oudessa Kerro Dego; Paulina A Pacha; Barbara E Gillespie; Gina M Pighetti
Journal:  Animals (Basel)       Date:  2020-04-25       Impact factor: 2.752

5.  Differential response of bovine mammary epithelial cells to Staphylococcus aureus or Escherichia coli agonists of the innate immune system.

Authors:  Florence B Gilbert; Patricia Cunha; Kirsty Jensen; Elizabeth J Glass; Gilles Foucras; Christèle Robert-Granié; Rachel Rupp; Pascal Rainard
Journal:  Vet Res       Date:  2013-06-11       Impact factor: 3.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.